About this file

This is a federal research solicitation for the development of shelf-stable nucleic acid synthesis reagents for field-deployable diagnostics under the Chemical and Biological Defense Program (CBDP).

The objective is to develop novel, shelf-stable reagents for nucleic acid synthesizers that enable the creation of high-quality oligonucleotides for rapid diagnostic test development at the point of need in 30 days within far-forward, expeditionary environments. Current nucleic acid synthesis reagents require cold chain storage at 4°C with limited shelf lives, rendering them impractical for resource-constrained or remote locations. The required reagents must remain effective at room temperature (20-25°C), perform reliably across military operationally relevant conditions from -20°C to 55°C, maintain an extended shelf life of at least 12 months, and perform at levels equal to or exceeding existing reagents. The CBDP also seeks significantly improved yield of synthesized nucleic acids to enable production of oligonucleotides with higher concentrations and volumes suitable for generating multiple high-quality molecular assay reagents per synthesis run.

Phase I will demonstrate feasibility of producing shelf-stable reagents with enhanced stability and shelf life by developing and testing prototype reagents comparable to current standard reagents. Success will be measured by comparing novel reagent performance with standard reagents using analytical techniques such as High-Performance Liquid Chromatography (HPLC) and mass spectrometry. Phase II will optimize formulation and manufacturing processes, scale up production, and conduct comprehensive stability testing, delivering a pre-production prototype kit evaluated by a government-identified independent laboratory. Phase III will transition the technology to commercial production and distribution through partnerships with reagent manufacturers and diagnostic companies, securing regulatory approvals if necessary, and developing marketing and sales strategies. Beyond DoD applications, these reagents have dual-use potential for commercial diagnostic companies, academic research laboratories, and public health organizations for rapid assay development in resource-limited settings. No technical point of contact is provided in the document.

View the file

Other files

File Type Posted
CBD_SBIR_25.4_R12.pdf PDF

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

CBD254-010: Shelf-Stable Nucleic Acid Synthesis Reagents for Field-Deployable Diagnostics

PROJECTED CMMC LEVEL REQUIREMENT:

N/A

TECHNOLOGY AREAS:

Bio Medical | Chem Bio Defense

MODERNIZATION PRIORITIES:

Biotechnology

KEYWORDS:

Expeditionary, Far-Forward, Diagnostics, Rapid Assay Development, Point-of-Need, Nucleic Acid Synthesizer, Manufacturing, Stability, Molecular Assay, Laboratory-Developed Test

ADDITIONAL INFORMATION

N/A

OBJECTIVE:

Develop novel, shelf-stable reagents for nucleic acid synthesizers that enable the creation of high-quality oligonucleotides for rapid diagnostic test (RDT) development at the point of need in 30 days in a far-forward, expeditionary environment

DESCRIPTION:

The Chemical and Biological Defense Program (CBDP) faces a critical challenge: the need for rapid, deployable diagnostic capabilities in far forward or expeditionary environments. Maintaining the health and readiness of the total force hinges on the ability to rapidly develop and deploy diagnostic assays in response to emerging threats and infectious diseases. However, current technologies present significant limitations. Existing nucleic acid synthesizers rely on reagents that demand cold chain storage at 4°C and possess limited shelf lives. These requirements render them impractical for use in resource-constrained or remote locations, hindering the rapid development and deployment of laboratory-developed tests (LDTs) precisely where they are most needed – at the point of need. To overcome these obstacles, there is an urgent requirement for nucleic acid synthesis reagents exhibiting exceptional stability. These reagents must remain effective at room temperature, perform reliably across a broad range of military operationally relevant conditions, from -20°C to 55°C, and maintain an extended shelf life of at least 12 months, all while performing at a level equal to or exceeding existing reagents. Beyond stability and shelf life, the CBDP is interested in developing reagents that significantly improve the yield of synthesized nucleic acids. This enhanced yield would enable the production of oligonucleotides with higher concentrations and volumes, ideally suited for generating multiple high-quality nucleic acid based molecular assay reagents per synthesis run.

PHASE I:

The objective of Phase I is to demonstrate the feasibility of producing nucleic acid synthesis reagents with enhanced stability and shelf life. This will involve developing and testing prototype reagents that meet or exceed the performance of current standard reagents of nucleic acid synthesizers. The prototype reagents should demonstrate stability at room temperature (20-25°C) for an extended amount of time prior to use, function in the device outside of the normal operating temperature range and maintaining equivalent performance to standard reagents. Success will be measured by comparing the performance of the novel reagents with standard reagents in synthesizing a control oligonucleotide sequence, assessing yield and purity using standard analytical techniques (e.g., High-Performance Liquid Chromatography (HPLC), mass spectrometry).

PHASE II:

Phase II will focus on optimizing the formulation and manufacturing process for the shelf-stable reagents, scaling up production, and conducting comprehensive stability testing. The deliverable will be a pre-production prototype kit of reagents suitable for use in a commercially available nucleic acid synthesizer. The reagents should demonstrate stability at room temperature (20-25°C) for at least 12 months, function in the device outside of the normal operating temperature range and maintain equivalent performance to standard reagents. The prototype kit will be evaluated by a government identified independent laboratory to assess its performance in synthesizing a panel of relevant oligonucleotide sequences for nucleic acid based molecular assay reagents.

PHASE III DUAL USE APPLICATIONS:

PHASE III: Phase III will focus on transitioning the technology to commercial production and distribution. This will involve securing partnerships with reagent manufacturers and diagnostic companies, obtaining regulatory approvals (if necessary), and developing a comprehensive marketing and sales strategy. Further optimization of the reagent formulation and packaging may be required to meet specific customer needs and market demands.

The ultimate goal is to develop reagents that perform reliably across a broad range of military operationally relevant conditions, from -20°C to 55°C, and maintain an extended shelf life of at least 12 months, all while performing at a level equal to or exceeding existing reagents, enabling the rapid development and deployment of diagnostic assays in far-forward and expeditionary environments.

PHASE III DUAL USE APPLICATIONS: Beyond DoD applications, these reagents can be used by commercial diagnostic companies, academic research labs, and public health organizations for rapid assay development and deployment in resource-limited settings.

REFERENCES:

Swierczewski B, Simons M. Diagnostics in a Forward Deployed Setting. Mil Med. 2017 Sep.,182(S2):11-16.

doi: 10.7205/MILMED-D-17-00069. PMID: 28885919.

1.

Yeh KB, Wood H, Scullion M, Russell JA, Parker K, Gnade BT, Jones AR, Whittier C, Mereish K. Molecular Detection of Biological Agents in the Field: Then and Now. mSphere. 2019 Dec 11.,4(6):e00695-19. doi:

10.1128/mSphere.00695-19. PMID: 31826970., PMCID: PMC6908421.

2.

TECHNICAL POINT OF CONTACT (TPOC):

None

File details come from the government source that posted it. Updated .